Onyx Pharma (ONXX) Affirms Trading Halt Ahead of FDA Meeting on NDA for Kyprolis
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Join SI Premium – FREE
Onyx Pharma (Nasdaq: ONXX) announced the NASDAQ has halted trading of the company's common stock ahead of the FDA's Oncologic Drugs Advisory Committee meeting this afternoon to discuss the company's New Drug Application for Kyprolis™ (proposed brand name for carfilzomib) under the accelerated approval pathway.
The stock was halted up nearly 0.7 percent at $44.56.
The stock was halted up nearly 0.7 percent at $44.56.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- loanDepot receives NYSE non-compliance notice over stock price
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
Corporate News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
